PERV-B RBD Ligands for SMVT Surface Detection and Quantification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for specific ligands that can target the sodium-dependent multivitamin transporter (SMVT) for diagnostic purposes, as existing knowledge on receptor binding domains (RBDs) of retrovirus envelope proteins has limited the development of probes for detecting and quantifying SMVT on the cell surface.
Innovation Solution
The use of ligands derived from the receptor-binding domain (RBD) of the porcine endogenous retrovirus type B (PERV-B) envelope protein to detect and quantify SMVT on the cell surface, which can be labeled for diagnostic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If ligands derived from PERV-B RBD are used to detect SMVT, then diagnostic capability for SMVT-related diseases is improved, but previous limited knowledge on RBD targets restricted probe development
Solution Approach 1:
The patent uses PERV-B RBD ligands as intermediary molecules that specifically bind to SMVT transporter on cell surfaces. These ligands serve as mediators between the diagnostic system and the target transporter, enabling detection and quantification of SMVT levels in various diseases including cancer and neurodegenerative disorders
Solution Approach 2:
The patent modifies and optimizes the PERV-B RBD ligand structure to enhance its binding affinity and specificity for SMVT. By changing parameters such as ligand concentration, incubation time, and detection methods (flow cytometry, ELISA, immunofluorescence), the system achieves precise measurement of SMVT levels
2Reliability
If specific ligands targeting SMVT are developed, then diagnostic accuracy for diseases like cancer and neurodegenerative disorders is improved, but existing retrovirus RBD knowledge was insufficient for probe development
Solution Approach 1:
The patent performs preliminary identification and characterization of PERV-B RBD ligands that specifically target SMVT before clinical application. This preliminary work includes validating the ligand-SMVT interaction, determining binding kinetics, and establishing detection protocols, which lays the foundation for reliable diagnostic applications
Solution Approach 2:
The patent establishes feedback mechanisms where SMVT binding by PERV-B RBD ligands is detected and measured using various techniques (flow cytometry, ELISA, immunofluorescence). This feedback information is used to quantify SMVT levels and diagnose diseases, while also providing insights that expand knowledge about RBD-target interactions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the detection and quantification of SMVT levels in biological samples, facilitating the diagnosis of SMVT-related diseases such as cancer, neurodegenerative diseases, and other conditions by specific binding and imaging techniques.
Implementation Method 1
The use of ligands derived from the receptor-binding domain (RBD) of the porcine endogenous retrovirus type B (PERV-B) envelope protein to detect and quantify SMVT on the cell surface
Data Source
AI summary
Methods for detecting and/or measuring the level of sodium-dependent multivitamin transporter (SMVT) in a biological sample. The methods include the steps of: (a) contacting the biological sample with a PERV-B.RBD ligand, a variant and/or a fragment thereof; and, detecting and/or measuring the binding of the PERV-B.RBD ligand, variant and/or fragment thereof to SMVT.